NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second fiscal quarter ended December 31, 2025. “This quarter was highlighted by continued strong Ryoncil® sales and the establishment of a new lower-cost non-dilutive financing facility both of which enable greater flexibility for strategic partnerships and pursuit of label expansion for Ryon ...

Agenus (NasdaqCM:AGEN) Update / briefing January 28, 2026 04:00 PM ET Speaker4Good afternoon, everyone, and thank you for joining us today. I'm Stefanie Perna-Nacar, Chief Communications Officer at Agenus, and welcome to our first stakeholder webcast of 2026. Today's discussion comes at a meaningful moment for our company, one shaped by important progress across patient access, clinical development, and operational readiness as we enter a pivotal year for Agenus and for the patients we serve. Before we begi ...

Article contentThis press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “exp ...

After failing to sustain an early move to the upside, the major U.S. stocks indexes quickly gave back ground and spent much of the rest of Wednesday's session lingering near the unchanged line. The major averages eventually ended the day narrowly mixed. While the S&P 500 edged down 0.57 points or less than a tenth of a percent to 6,978.03, the Dow crept up 12.19 points or less than a tenth of a percent to 49,015.60 and the Nasdaq rose 40.35 points or 0.2 percent to 23,857.45.The choppy trading on Wall Stre ...

- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ PlatformTM drug optimization technology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) applicat ...

THOUSAND OAKS, Calif., Jan. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of ...

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/vistagen-therapeutics-inc-loss-submission-form/?id=183258&from=3 CLASS ...

ATLANTA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) complied with federal securities laws. On January 28, 2026, REGENXBIO announced it “received communication from the U.S. Food and Drug Administration (“FDA”) that the Company’s Investigational New Drug applications for both its Phase I/II trial evaluating RGX-111 for Mucopolysaccharidosis type I and its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis ...

REGENXBIO Inc. (NASDAQ:RGNX) shares are tumbling on Wednesday with a session volume of 3.83 million versus an average volume of 684.271 thousand.The move follows a regulatory update that has raised concerns among investors. The U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapies.FDA Holds REGENXBIO’s Gene Therapy ProgramsThe FDA’s decision affects REGENXBIO’s RGX-111 and RGX-121 programs, which are aimed at treating rare genetic disorders.The clinical hold wa ...

Key Takeaways FOLD stands out after agreeing to a $14.50-per-share buyout by BioMarin, expected to be closed in Q2 2026.FOLD's Galafold drove over 80% of sales in 9M 2025, while Pombiliti plus Opfolda showed strong initial growth.RIGL's revenues are powered by Tavalisse, with added momentum from Rezlidhia and newly acquired Gavreto.Amicus Therapeutics (FOLD) and Rigel Pharmaceuticals (RIGL) appeal to growth-focused investors as they target rare diseases, where small patient populations can still support str ...